Navigation Links
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
Date:10/11/2007

AURORA, ON, Oct. 11 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864) announced today the addition of Kenneth D. Hatch, M.D., as a new medical advisor to the Company. Dr. Hatch will provide guidance to Helix on its clinical-stage compound, Topical Interferon Alpha-2b, for the treatment of conditions caused by HPV. Dr. Hatch is a professor of obstetrics and gynecology at the University of Arizona.

"Dr. Hatch complements our medical advisory team and brings additional strength to Helix' expertise in the field of gynecology and pre-invasive diseases of the cervix", said John Docherty, vice president, corporate development at Helix. "We are very pleased to establish this relationship with Dr. Hatch, and expect that he will be an invaluable asset to the Company as we continue to move forward with the preparations for our planned IND/CTA filings for Topical Interferon Alpha-2b".

Previously, Dr. Hatch was president of the American Society of Colposcopy and Cervical Pathology. Dr. Hatch has also presided as secretary-treasurer of the International Federation of Colposcopy and Cervical Pathology, and as president of the Society of Gynecologic Oncologists.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by HPV, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker symbol "HBP".

This News Release contains certain forward-looking statements and information regarding Helix's product development initiatives, Topical Interferon Alpha-2b and L-DOS47. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "expect", "planned", "developing", and "initiatives". Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous factors, including without limitation, Helix's need for additional capital in the near term and in future, which may not be available on acceptable terms or at all; uncertainty whether the IND/CTA filings for Topical Interferon Alpha-2b will be filed as planned; research and development risks; and uncertainty whether Topical Interferon Alpha-2b, L-DOS47, or any other product will be developed and marketed successfully as a drug or at all. See a description of other risks and uncertainties affecting Helix and its business, as contained in Helix's latest Annual Information Form and other filings with the Canadian Securities Regulatory Authorities at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those beliefs, opinions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:2/8/2016)... 2016 Novan, Inc. today announced that Director Robert ... Directors of Novan. In addition, Robert Keegan has been ... Carolina . --> North Carolina ... received a total of $32.8 million of net proceeds in a ... network originating throughout the Research Triangle area of North ...
Breaking Biology Technology:
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
Breaking Biology News(10 mins):